Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perimenstrual Repetitive Greater Occipital Nerve Blockade for Menstrual Migraine
NCT07576309Completed
- Sponsor
- Sağlık Bilimleri Üniversitesi
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in menstrual migraine comparing Active Treatment: 0.5% Bupivacaine with Placebo: Normal Saline (2 arms). Primary endpoint: Visual Analog Scale at 6 months. Started Oct 2024; status: completed.
02
Drugs
bupivacaine
03
Conditions
menstrual migraine
Beyond the preview
Go deeper on NCT07576309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07576309.